Inpharma 1574 - 10 Feb 2007

■ Virologic suppression at 3 years is more likelywith nevirapine or efavirenz than with abacavir afterswitching from protease inhibitor (PI)-based therapy toregimens based on these drugs, according to long-term data from the Nevirapine/Efavirenz/Abacavir(NEFA) study.* In that multicentre, open-label study,460 patients were randomised to replace their PI-based regimen with one based on nevirapine twicedaily (n = 155), efavirenz once daily (n = 156) orabacavir twice daily; the original follow-up was at1 year. At the extended 3-year follow-up, virologicsuccess was observed in 93.5% of nevirapinerecipients and 92.9% of efavirenz recipients, comparedwith 80.5% of abacavir recipients, in the intent-to-treatanalysis.* See Inpharma 1405 p12; 800943523

Boehringer-Ingelheim. Data Published in AIDS Show Viramune(R)(nevirapine) Achieves Durable Benefit in Switch Patients. Media Release : 31Jan 2007. Available from: URL: http://www.boehringer-ingelheim.com 809072057

1

Inpharma 10 Feb 2007 No. 15741173-8324/10/1574-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved